Copyright
©The Author(s) 2024.
World J Clin Oncol. Jan 24, 2024; 15(1): 115-129
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.115
Published online Jan 24, 2024. doi: 10.5306/wjco.v15.i1.115
Figure 1 Identification of hub targets and the Kyoto Encyclopedia of Genes and Genomes pathways.
A: Venn diagram illustrating overlap of targets between GSE16558 and GSE116294 datasets; B: Target protein–protein interaction (PPI) network; C: Top 15 hub genes identified using CytoHubba plugin; D: Two primary clusters of PPI scored using themolecular complex detection plugin; E: Ranking of top 10 hub genes within PPI network; F: The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis; G: Gene Set Enrichment Analysis of nuclear factor -κB signaling pathway. NK: Nuclear factor.
- Citation: Song Y, Zhang HJ, Song X, Geng J, Li HY, Zhang LZ, Yang B, Lu XC. Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma. World J Clin Oncol 2024; 15(1): 115-129
- URL: https://www.wjgnet.com/2218-4333/full/v15/i1/115.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i1.115